Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by Benedict16thon Oct 17, 2020 7:35am
74 Views
Post# 31733812

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:LATAM'S moat

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:LATAM'S moatSo, 18 months ago GUD MNGT “smart” investors team went on an expensive campaign to repulse and demonize Mr. Meir investment strategies despite the fact that Mr. Meir company Medison graciously paid GUD investors million of dollars in dividends. GUD never paid a dividend.  GUD MNGT portrait Mr. Meir strategy a bad and risky and that he had no expertise in inventing in Canada.  Move forward 18 months GUD buys GBT and loses nearly 100 million dues to the Real depreciation. So if Mr Meir was not expert in Canada was/is GUD MNGT expert in Latam?   Well, 100 million dollars later as a loss obviously not.  Second GUD share price since 18 months ago lost 25%.  We do not know how well or how badly Medison is doing but we certainly hell know how bad is GUD doing. Move forward  18 month later GUD MNGT did precisely what they warned investors Meir would do investors.  Risk Destroy investors capital. 
Bullboard Posts